Anixa Biosciences (ANIX)
Develops cancer vaccines and ovarian-cancer CAR-T therapy through institutional collaborations.
Something off on this page? Send us feedback.
Develops cancer vaccines and an ovarian-cancer CAR-T therapy, alongside limited legacy patent licensing. The development model advances licensed technologies with research institutions and subcontractors; revenue-generating operations are not anticipated for the foreseeable future.
Cancer Vaccines and CAR-T Therapies are the primary reportable businesses, with Other including limited legacy patent licensing. Cancer Vaccines covers breast- and ovarian-cancer vaccines and early discovery work for lung, colon, and prostate cancers; CAR-T Therapies centers on an ovarian-cancer program.
Development relies on licensed technology and collaboration with Moffitt, Cleveland Clinic, and subcontractors rather than a large internal organization. The breast-cancer vaccine and CAR-T therapeutic are in clinical development, while the ovarian vaccine is preclinical.
The work is concentrated in cancer immunotherapy. Commercialization depends on successful development, regulatory approvals, and the ability to work with partners.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Apr 30, 2026Cash & short-term investments $13.7M · Total debt $184.0K · Total assets $14.9M · Shareholders' equity $14.5M
- Revenue
- $0
- Operating income
- −$2.6M
- Net income
- −$2.6M
No dividends on record.
| Institutions65 holders · as of Jun 30, 2026 | 15.74% | 5.35M shares | |
| Insiders4 holders · as of Aug 3, 2026 | 28.96% | 9.85M shares | |
| Otherremainder | 55.30% | 18.82M shares |
34.02M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Amit Kumar1Insiderdirector, officer: Chief Executive Officer | 18.40% | 6.17M | 13Dfiled Aug 3, 2026 ↗ |
Michael Catelani2Insiderofficer: President, COO, & CFO | 7.25% | 2.47M | 13Dfiled Jan 6, 2026 ↗ |
Vanguard Capital Management LLCInstitution | 3.91% | 1.33M | 13Fas of Jun 30, 2026 |
Lewis H. jr TittertonInsiderdirector | 2.90% | 986,967 | Form 4filed Jul 20, 2026 ↗ |
UBS Group AGInstitution | 1.72% | 585,430 | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
- Amit Kumar's transaction reports restate only vehicles that traded; the 2025 ownership statement (6.17M) plus the 87.7K net shares acquired since is used instead.
- Michael Catelani's transaction reports restate only vehicles that traded; the 2026 ownership statement (2.47M) is used instead.
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 31, 2026 | Amit Kumar | director, officer: Chief Executive Officer | +5,000 | $3.47 |
| Jul 27, 2026 | Amit Kumar | director, officer: Chief Executive Officer | +8,188 | $3.41 |
| Jul 24, 2026 | Amit Kumar | director, officer: Chief Executive Officer | +3,000 | $3.73 |
| Jul 20, 2026 | Amit Kumar | director, officer: Chief Executive Officer | +5,000 | $3.46 |
| Jul 20, 2026 | Lewis H. jr Titterton | director | +12,000 | $3.47 |
- Greenwich LifeSciences
Phase III peptide vaccine for breast-cancer recurrence prevention
- Immatics
PRAME-directed TCR-T therapy in clinical ovarian-cancer studies
- Elicio Therapeutics
Lymph-node-targeted therapeutic cancer vaccine for KRAS tumors
- PDS Biotechnology
Phase III immunotherapy for HPV16-positive head-and-neck cancer
- Iovance Biotherapeutics
Autologous TIL cell-therapy platform for solid tumors
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Anixa Biosciences | $3.26 | +3.44% | $106.5M | — | — | — | — |
| Greenwich LifeSciences | $15.68 | −0.70% | $231.0M | — | — | — | — |
| Immatics | $9.59 | +0.84% | $1.27B | — | — | 26.3 | +113.0% |
| Elicio Therapeutics | $2.55 | −0.39% | $48.6M | — | — | — | — |
| PDS Biotechnology | $0.2105 | −2.82% | $11.9M | — | — | — | — |
| Iovance Biotherapeutics | $8.67 | +0.41% | $3.85B | — | — | 11.8 | +65.7% |
| Median | — | — | 19.1 | +89.3% |